Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2026-05-21 Capital/Financing Update
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
本公司對新加坡子公司Lotus International Pte. Ltd.資金貸與案
Capital/Financing Update Classification · 60% confidence The document is an official announcement on the Taiwan MOPS system disclosing a ‘資金貸與案’ – a financing transaction (loan of funds) by the listed company to its subsidiary. It is not a full financial report but a corporate financing update under the company’s internal financing/loan policies. This aligns with the Capital/Financing Update category (CAP).
2026-05-21 Chinese
本公司董事會通過子公司Alvogen Korea向OM PHARMA SA購買韓國藥證案
Regulatory Filings Classification · 82% confidence The document is a Taiwanese regulatory disclosure (“公開資訊觀測站”) of a board resolution approving a subsidiary’s purchase of drug licenses and IP (an asset acquisition). It is not a full financial report, earnings release, or any of the other more specific categories, nor is it a notice of share issuance or merger bid. As a miscellaneous regulatory announcement, it falls under Regulatory Filings (RNS).
2026-05-21 Chinese
115年05月法人說明會簡報 — 179520260515E001.pdf
Investor Presentation Classification · 93% confidence The document is a slide presentation titled “1Q26 Financial Results” with a Safe Harbor statement, agenda, business highlights, detailed quarterly financial tables, pipeline updates, and strategic outlook. It is designed as an investor-facing deck rather than the official interim report or press release. This matches the definition of an Investor Presentation (IP).
2026-05-15 English
115年05月法人說明會簡報 — 179520260515M001.pdf
Investor Presentation Classification · 95% confidence The document is a slide‐based presentation (“法說會” or earnings conference) covering 1Q26 financial highlights, detailed income statement data, segment metrics, forward‐looking statements, product pipeline, and strategy. It is not a statutory interim report, proxy, or press release; it is clearly an investor presentation deck. Therefore it fits the Investor Presentation (IP) category.
2026-05-15 English
115年05月法人說明會簡報
Investor Presentation Classification · 82% confidence The document is a notice listing company ‘legal person’ (institutional investor) presentation sessions, including date/time, location, summary and links to presentation files (Chinese/English). This corresponds to investor presentation materials rather than financial statement releases, management changes, or regulatory filings. It fits the “Investor Presentation” category.
2026-05-15 Chinese
115年年報及股東會資料 — 2026_1795_20260616F13.pdf
AGM Information Classification · 85% confidence The document is the official “議事手冊” (meeting handbook) for the 115th Annual General Meeting of 美時化學製藥股份有限公司. It contains the AGM agenda, reports, approval items, discussion items, attachments of the annual business report, financial statements, audit report, dividend distributions, charter amendments and other materials provided to shareholders at the meeting. This aligns with the definition of AGM Information (AGM-R): presentations and materials shared during the Annual General Meeting.
2026-05-15 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.